MDS Pharma Services enhances scientific capabilities with API 4000 LC/MS/MS system
(August 16, 2001; Montreal, Quebec) — MDS Pharma Services has become the first contract research organization to purchase the API 4000 LC/MS/MS System from Applied Biosystems/MDS Sciex. The API 4000 is at the pinnacle of triple quadrupole platforms, which are used in bioanalytical research during the drug discovery and development process.
The API 4000 system creates a new standard for instrumentation ruggedness and reliability, enabling even greater productivity in the laboratory. It presents a tenfold increase in sensitivity for many analytes, compared to other triple quadrupole LC/MS/MS systems.
"We have, in fact, plans in place for several API 4000 LC/MS/MS systems," said Jim Hulse, senior vice president, bioanalytical, MDS Pharma Services. "The capabilities of the API 4000 are of critical importance. More and more drugs with highly specific pharmacological activities and lower daily dosage recommendations are being developed through pharmaceutical pipelines. The lower the dosage recommendation, the greater the sensitivity needed in laboratory instrumentation to analyze samples. The API 4000 will be crucial in determining the safety and efficacy of many new drugs."
The system is fully integrated with powerful data acquisition and processing capabilities. As a result, the system provides much faster access to information than its predecessors. It represents the best detection limit and highest throughput capacity available. It also enables automated MS to MS/MS acquisition of data for maximum extraction of information from a single LC/MS run.
"Our first API 4000 is now being employed in our laboratory in St. Laurent, Quebec," continued Hulse. "We are encouraging our clients to send us their most difficult bioanalytical research assignments, as the API 4000 will most certainly be able to help."
As the global leader in bioanalytical services, MDS Pharma Services offers extensive expertise in method development, rapid sample analysis, custom assay development, biochemical markers, and statistical and pharmacokinetic services. This advanced technology, along with highly-skilled scientific staff and extensive emphasis on customer service, ensure reliable client solutions. With bioanalytical laboratories worldwide, equipped with more than 70 LC/MS/MS instruments, and over 700 available assays, MDS Pharma Services rapidly delivers accurate results.
MDS Pharma Services offers a full spectrum of resources to meet the drug discovery and development needs of the pharmaceutical and biotechnology industries. With facilities in more than 18 countries, the company applies advanced scientific and technological expertise to each stage of the drug discovery and development process: discovery, preclinical, early clinical research (phases I-IIa), bioanalytical, global clinical research (phases IIb-IV), and central lab.
MDS Pharma Services is part of MDS Inc. (TSE: MDS; NYSE: MDZ), an international health and life sciences company. In many of its products and services, it is among the largest and most respected companies in the world. At MDS, the focus is on fighting disease. It does this by providing laboratory testing, imaging products, research services to speed discovery and development of new drugs, therapy systems for planning and delivery of cancer treatments, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. MDS employs more than 10,000 highly skilled people in its global operations on five continents. Detailed information abut the company is available at the MDS Web site at www.mdsintl.com or by calling 1-888-MDS-7222, 24 hours a day.
